BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1942 related articles for article (PubMed ID: 19933538)

  • 21. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
    White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
    Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: A randomized comparison of sugammadex reversal with spontaneous recovery.
    Rahe-Meyer N; Berger C; Wittmann M; Solomon C; Abels EA; Rietbergen H; Reuter DA
    Anaesthesist; 2015 Jul; 64(7):506-12. PubMed ID: 26126940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
    Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
    Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial.
    Asztalos L; Szabó-Maák Z; Gajdos A; Nemes R; Pongrácz A; Lengyel S; Fülesdi B; Tassonyi E
    Anesthesiology; 2017 Sep; 127(3):441-449. PubMed ID: 28640017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
    Sorgenfrei IF; Norrild K; Larsen PB; Stensballe J; Ostergaard D; Prins ME; Viby-Mogensen J
    Anesthesiology; 2006 Apr; 104(4):667-74. PubMed ID: 16571960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial.
    Tassonyi E; Pongrácz A; Nemes R; Asztalos L; Lengyel S; Fülesdi B
    Anesth Analg; 2015 Aug; 121(2):373-80. PubMed ID: 25923435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Jones RK; Caldwell JE; Brull SJ; Soto RG
    Anesthesiology; 2008 Nov; 109(5):816-24. PubMed ID: 18946293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.
    Schaller SJ; Lewald H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1097-108. PubMed ID: 27463265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sugammadex: A Review of Neuromuscular Blockade Reversal.
    Keating GM
    Drugs; 2016 Jul; 76(10):1041-52. PubMed ID: 27324403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
    Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The concept behind sugammadex.
    Epemolu O; Bom A
    Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery.
    Dahl V; Pendeville PE; Hollmann MW; Heier T; Abels EA; Blobner M
    Eur J Anaesthesiol; 2009 Oct; 26(10):874-84. PubMed ID: 19455040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of neuromuscular block with sugammadex: a comparison of the corrugator supercilii and adductor pollicis muscles in a randomized dose-response study.
    Yamamoto S; Yamamoto Y; Kitajima O; Maeda T; Suzuki T
    Acta Anaesthesiol Scand; 2015 Aug; 59(7):892-901. PubMed ID: 25962400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Sugammadex in Patients With Obesity: A Pooled Analysis.
    Monk TG; Rietbergen H; Woo T; Fennema H
    Am J Ther; 2017; 24(5):e507-e516. PubMed ID: 26398716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
    Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
    Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
    Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    Brueckmann B; Sasaki N; Grobara P; Li MK; Woo T; de Bie J; Maktabi M; Lee J; Kwo J; Pino R; Sabouri AS; McGovern F; Staehr-Rye AK; Eikermann M
    Br J Anaesth; 2015 Nov; 115(5):743-51. PubMed ID: 25935840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.